Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has received the European Medicines Agency (EMA) acceptance to review its marketing authorization application (MAA) for perampanel (E2007).
Subscribe to our email newsletter
Eisai discovered perampanel (E2007) is a AMPA receptor antagonist indicated as a treatment for partial-onset seizures linked with epilepsy.
The company’s submission of the application was supported by the results from three Phase III double-blind, dose-escalation, randomized, place-controlled studies, 306, 305 and 304, which involved around 1,480 patients in the trials.
Each of the studies demonstrated consistent results in the efficacy and tolerability of perampanel given as therapy in patients with refractory partial seizures.